773TiPPRODIGE 51 - GASTFOX: Phase III randomised trial evaluating FOLFOX with or without DOCETAXEL (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric adenocarcinoma

A. Zaanan 1 E. Samalin 2 C. Louvet 3 C. Montérymard 4, 5 F. Khemissa 6 O. Bouche 7 S. Louafi 8 F. Ghiringhelli 9 P. Bernard 10 B. Chibaudel 11 P. Artru 12 Y. Molin 13 N. Baba-Hamed O. Romano 14 T. Aparicio 15 P. Michel 16 P. Rougier 17 D. Tougeron 18 S. Manfredi 19, 4, 20 J. Taieb 1
Type de document :
Communication dans un congrès
the 42nd ESMO Congress (ESMO 2017), Sep 2017, Madrid, Spain. Annals of Oncology, Volume 28, Issue suppl_5, 28 (suppl_5), 2017, Abstract Book of the 42nd ESMO Congress (ESMO 2017) 8–12 September 2017, Madrid, Spain. 〈https://academic.oup.com/annonc/article/28/suppl_5/mdx369.155/4108858/773TiPPRODIGE-51-GASTFOX-Phase-III-randomised〉. 〈10.1093/annonc/mdx369.155〉
Liste complète des métadonnées

https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01632489
Contributeur : Lnc - Université de Bourgogne <>
Soumis le : vendredi 10 novembre 2017 - 11:54:05
Dernière modification le : vendredi 27 juillet 2018 - 15:04:02

Lien texte intégral

Identifiants

Citation

A. Zaanan, E. Samalin, C. Louvet, C. Montérymard, F. Khemissa, et al.. 773TiPPRODIGE 51 - GASTFOX: Phase III randomised trial evaluating FOLFOX with or without DOCETAXEL (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric adenocarcinoma. the 42nd ESMO Congress (ESMO 2017), Sep 2017, Madrid, Spain. Annals of Oncology, Volume 28, Issue suppl_5, 28 (suppl_5), 2017, Abstract Book of the 42nd ESMO Congress (ESMO 2017) 8–12 September 2017, Madrid, Spain. 〈https://academic.oup.com/annonc/article/28/suppl_5/mdx369.155/4108858/773TiPPRODIGE-51-GASTFOX-Phase-III-randomised〉. 〈10.1093/annonc/mdx369.155〉. 〈hal-01632489〉

Partager

Métriques

Consultations de la notice

55